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(5Z)-carbacyclin discriminates between prostacyclin-
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1 (5E)- and (5Z)-carbacyclin are prostacyclin (PGI2) analogues endowed with antiaggregating and
vasodilator properties, which stimulate adenylate cyclase activity in membranes from human platelets
and cultured myocytes from rabbit mesenteric artery.
2 In platelets they display the same efficacy as prostaglandin E1 (PGE1), and hence PGI2, both as
activators of adenylate cyclase and as inhibitors of aggregation.
3 In contrast, in vascular smooth muscle cells (5Z)-carbacyclin fails to produce the same degree of
stimulation of the enzyme as PGI2, (5E)-carbacyclin and PGEI, nor does it induce the maximal
relaxation of the mesenteric artery as do the other prostaglandins.
4 (5Z)-carbacyclin is also able to antagonize the activation of adenylate cyclase and the relaxation
elicited by PGEI or PGI2 in the mesenteric artery, and therefore it displays partial agonist properties in
these cells.
5 We conclude that the receptors for PGI2 coupled to adenylate cyclase in platelets and vascular
smooth muscle cells are different from each other, because (5Z)-carbacyclin can discriminate between
them, being a partial agonist at myocyte but not at platelet level.
Introduction
Prostacyclin (PGI2) is the most potent inhibitor of
platelet aggregation (Moncada et al., 1976) and,
because of this property, it has many potential clinical
applications. However, prostacyclin has some draw-
backs which have so far limited a more widespread
clinical use. In fact, not only is it chemically and
metabolically unstable (Moncada et al., 1976; Johnson
et al., 1976), but it also displays potent vasodepressor
actions (Moncada et al., 1976; 1978), when often only
the anti-platelet effect is desired.
For these reasons, a great effort has been made
toward the development of PGI2 analogues more
suitable for clinical use (Whittle & Moncada, 1984).
The design of a PGI2 analogue endowed with a high
degree of selectivity for the platelet receptor will be
successful only if this receptor differs from that on
vasculature.
Because both inhibition of platelet aggregation and
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vasodilatation are supposed to be mediated by an
increase in intracellular adenosine 3':5'-cyclic mono-
phosphate (cyclic AMP) levels (Gorman et al., 1977;
Tateson et al., 1977; Miller et al., 1979; Kukovetz et
al., 1979; Lombroso et al., 1984; Oliva et al., 1984a,b),
through activation ofadenylate cyclase (AC), we have
addressed the problem of characterization of the
platelet and vascular receptors for PGI2 by investigat-
ing the activation of this enzyme in membranes from
human platelets and from rabbit vascular myocytes.
The evaluation in these systems of some prostacyclin
analogues (PGEI, 6B-PGI1, 6-keto-PGEI), so far has
not revealed any major difference between the platelet
and the vascular receptors for PG12 coupled to
adenylate cyclase (Lombroso et al., 1984; Oliva et al.,
1984 a,b).
We describe here further studies performed with
two epimers of carbacyclin (Morton et al., 1979)
(Figure 1) which share with PGI2 the antiaggregating
and vasodilator effects (Whittle et al., 1980), and
demonstrate that the 5Z epimer is able to discriminate
between the platelet and vascular receptor.
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Figure 1 Structures of prostacyclin (PGI2) and its analogues, the carbacyclins.
Methods Cell cultures
Materials
[8-14C1-adenosine triphosphate ([8-'4C]-ATP) and [8-
3H]-cyclic AMP were from New England Nuclear,
Boston, MA, U.S.A; ATP, cyclic AMP, guanosine
triphosphate (GTP), creatine phosphate, creatine
phosphokinase and sodium arachidonate were pur-
chased from Sigma Chemical Co., St. Louis, MO,
U.S.A. Prostacyclin (PGI2), PGE1, (5E)-carbacyclin
and (5Z)-carbacyclin were synthesized by the Upjohn
Co., Kalamazoo, MI, U.S.A., and supplied by The
Wellcome Research Laboratories, Beckenham, U.K.
The solutions of PGI2, which was stored in ethanol at
- 20'C, were freshly prepared immediately before use
in 1OmM Tris-HC1 buffer, pH 8. The other prosta-
glandins were dissolved in the same Tris buffer. In the
experiments with myocyte membranes, where the high
concentrations of (5Z)-carbacyclin gave solubility
problems, it was more convenient to dissolve and
dilute this prostaglandin, and therefore also the oth-
ers, with 40% ethanol in Tris buffer (to yield a final
ethanol concentration of 4% in the sample). The
inclusion of ethanol in the adenylate cyclase assay did
not modify the pattern of response to the prostaglan-
dins. Eagle's minimum essential medium Fl 1, foetal
calf serum, trypsin-EDTA, penicillin (10,000 u ml- 1),
streptomycin (1Omg ml'), tricine buffer (I M) and
non-essential amino acids (100 x) were purchased
from Grand Island Biological Co., Madison, WI,
U.S.A.; disposable culture flasks and petri dishes were
from Corning Glassworks, Amedfield, MA, U.S.A.
Male white New Zealand rabbits (2- 3 kg) were used.
Cultures of smooth muscle cells from intima-medial
layer of rabbit aorta and mesenteric arteries were
prepared according to the method of Ross (1971), as
previously described by Oliva et al. (1984b).
Preparation of membranes
Platelet concentrates (collected in citric acid/sodium
citrate/sodium phosphate/dextrose) from 3-4 healthy
male volunteers were pooled. A crude membrane
preparation (pellet at 27,000g) was prepared as des-
cribed by Lombroso et al. (1984).
Smooth muscle cell monolayers from rabbit mesen-
teric artery (used between the 8th and 14th passage)
were washed in 50mM Tris-HC1 buffer (pH 7.4),
harvested by scraping, pooled and the membrane
preparation (pellet at 15,000g) was obtained as des-
cribed by Oliva et al. (1984b).
Platelet aggregation studies
Blood was collected in 3.8% sodium citrate (9:1).
Platelet-rich plasma (PRP) and platelet-poor plasma
(PPP) were prepared as previously described (Tremoli
et al., 1979). Platelet count was adjusted to
300-400,0001d' by adding PPP. Prostaglandin in-
hibition of platelet aggregation was measured in PRP
samples stimulated by collagen 5 ng ll - using an
ELVI Logos aggregometer by the turbidimetric tech-
nique of Born (1962).
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Rabbit mesenteric artery studies
100 -
Spiral strips of rabbit mesenteric artery were prepared
and set up using the laminar-flow technique of
Ferreira & Costa (1976). The spirals were superfused
with Krebs solution of the following composition
(glP'): NaCl 6.9, KCl 0.35, KH2PO4 0.16, MgSO4.
7H20 0.29, CaCl2 0.28, glucose I and NaHCO3 2.1.
Flow rate was 0.2 ml min-', the buffer was kept at
370C and gassed with 95% 02 and 5% CO2. The
resting tone of the preparations was 1 g and contrac-
tions were recorded with isotonic transducers Mod.
7006 (Ugo Basile, Comerio, Italy) connected to a 2
channel Gemini recorder, Mod. 7070 (Ugo Basile).
The tissues were equilibrated for 2 h and subsequently
challenged with bolus injections of different agonists;
the volume of the injected bolus was 0.1 ml.
Adenylate cyclase assay
The standard assay mixture (final volume: 100gld)
contained: 10mM Tris-HCI buffer (pH 8); 0.10mM [8-
'4C]-ATP (50 dpm pmol '); 0.5mM [8-3H]-cyclic
AMP (approximately 360 dpm nmol- 1); 2mM
MgC12; 2mM creatine phosphate; 17umlL' crea-
tine phosphokinase; 10 AMGTP and the indicated
prostaglandins. The incubation, started with the addi-
tion of the membrane preparation (0.04-0.09 and
0.06-0.10mg protein per sample for platelet and
mesenteric membranes respectively), was carried out
at 30'C for 8 min. [8-3H]-cyclic AMP was included in
the assay mixture to permit correction for column loss
and for the possible effect ofphosphodiesterases (Katz
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Figure 3 Dose-response curves for the inhibition of
human platelet aggregation induced by collagen (5 ng
pl'): (-) (5E)-carbacyclin; (A) prostaglandin El; (0)
(5Z)-carbacyclin.
[8-'4C, 8-3H]-cyclic AMP was isolated and detected
according to Salomon et al. (1974). Protein concentra-
tions were determined according to Bradford (1976).
Expression of results
The results are expressed as mean ± s.d. of triplicate
determinations in one experiment, performed at least











Figure 2 Dose-response curves for the a
adenylate cyclase by different prostagland
branes of human platelets: (0) (5E)-carb
prostaglandin El; (0) (5Z)-carbacyclin.
The effect of increasing concentrations of (5E)-car-
bacyclin and (5Z)-carbacyclin on AC activity was
investigated in human platelet membranes and com-
pared with that of PGE1. Figure 2 shows that all the
prostaglandins were able to stimulate AC in a dose-
dependent fashion with approximately parallel curves,
and that they were equieffective (maximal stimulation:
5 fold). The concentrations eliciting half-maximal
stimulation (ECO) were 0.307 ± 0.162 JM 0.633 +
0.351 IAM and 2.83 ± 0.29 pM for (5E)-carbacyclin,
PGEI and (5Z)-carbacyclin, respectively.
(5Z)-carbacyclin was tested for its ability to inhibit
collagen-induced platelet aggregation (Figure 3) and
1 o-5' 1'ol-4 was found to induce the same maximal response as
PGE1 and (5E)-carbacyclin (100% inhibition). The
concentrations eliciting half-maximal inhibition (ICsO)
Lctivation of were 105 ± 32 nM, 145 ± 153 nM, and 1.96 ± 0.99
[ins in mem- AM, for (5E)-carbacyclin, PGE1 and (5Z)-carbacyclin,
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Figure 4 Dose-response curves for the activation of
adenylate cyclase by different prostaglandins in mem-
branes of myoctyes from rabbit mesenteric artery: (0)
(5E)-carbacyclin; (A) prostaglandin El; (0) (5Z)-car-
bacyclin.
Rabbit mesenteric arterial myocytes
In membranes of cultured smooth muscle cells from
rabbit mesenteric artery (5E)-carbacyclin, PGEI and
(5Z)-carbacyclin stimulated AC in a dose-dependent
fashion (Figure 4). However, at variance with the
results obtained in human platelet membranes, the
maximal stimulation attained with the two carbacy-
clins was different. In fact, (5E)-carbacyclin activated
AC to the same extent (3.5 fold) and approximately
with the same potency (EC50= 5.93 + 2.10 pM) as








0 10i510- 0-3 10
(5Z)-carbacyclin (M)
Figure 5 Dose-dependent effect of (5Z)-carbacyclin on
adenylate cyclase activity of myocytes in the absence (0)
and presence (A) of prostaglandin El 0.3 mM. UP< 0.01,
**P<0.001 when compared with stimulation by pros-
taglandin El alone.
Figure 6 Dose-dependent effect of prostaglandin El
(PGE1) on adenylate cyclase activity of myoctyes in the
absence (A) and the presence (0) of (5Z)-carbacyclin,
0.2 mM. UP< 0.001 when compared with corresponding
concentrations of PGEI alone.
In contrast, (5Z)-carbacyclin failed to reach the
same response elicited by the other two prostaglan-
dins, in that the maximal stimulation (attained at
0.4 mM) was 2 fold. (5Z)-carbacyclin had an EC50 of
0.104 ± 0.021 mM.
The lower efficacy of (5Z)-carbacyclin suggested
that it might act as a partial agonist. In order to
evaluate this hypothesis, the effect of increasing
concentrations of (5Z)-carbacyclin on PGE1-
stimulated AC activity was investigated. As shown in
Figure 5, (5Z)-carbacyclin displayed antagonistic














Figure 7 Dose-dependent effect of prostacyclin (PGI2)
on adenylate cyclase activity of myocytes in the absence
(U) and presence (0) of (5Z)-carbacyclin 1 mM.
**P< 0.001 when compared with corresponding concen-
tration ofPGI2 alone. The column represents the stimula-


























Figure 8 Dose-response curves for the relaxation of
rabbit mesenteric artery: 100% relaxation was taken as
the maximal effect attainable with prostacyclin (PG12);
(0) (5E)-carbacyclin; (0) (5Z)-carbacyclin; (A) pros-
taglandin El; (-) PG12-
stimulation of AC induced by 0.3 mM PGEI. (5Z)-
carbacyclin also antagonized the activation of AC
elicited by 40 pM (5E)-carbacyclin (data not shown).
The agonist/antagonist properties of (5Z)-carbacy-
clin are further demonstrated by the experiment of
Figure 6, where a dose-response curve for PGE1 in the
presence and absence of a fixed concentration of (5Z)-
carbacyclin is shown. As expected from a partial
agonist (Ariens et al., 1964), this carbacyclin
stimulates AC at low concentrations of the full agonist
PGEI, while it antagonizes the effects of higher
concentrations of the latter.
The particular cell line used in the experiment
shown in Figure 6 displayed a lower degree of
stimulation than those used in other experiments (see,
e.g. Figure 4), and therefore the difference between
PGO2 and (5Z)-carbacyclin efficacies appears smaller
than in other experiments. However, as already discus-
sed (Oliva et al., 1 984b), the pattern ofAC stimulation
A
PGI2, ng 140
(5Z)-C, ng 140 280
was comparable to that of the other membrane
preparations.
The experiment depicted in Figure 7 demonstrates
that the partial agonist properties of (5Z)-carbacyclin
are displayed not only versus PGEI, but also versus
PGI2, as one would expect if the two latter prostaglan-
dins act through the same receptor. In fact, a maximal-
ly activating concentration of (5Z)-carbacyclin (1 mM)
elicited a lower enzyme stimulation than PG12 (which
was equieffective with PGE1). Furthermore, this same
concentration of (5Z)-carbacyclin was not additive
with an equieffective concentration of PGI2 (2 JtM),
while it was able to inhibit the enzyme activation
elicited by higher concentrations ofPGO2 (5 pLM). These
results are in line with the theory of partial agonist
effects (Ariens et al., 1964).
The effect of increasing amounts of the various
prostaglandins in relaxing rabbit mesenteric artery
was also investigated. Figure 8 shows that (5Z)-car-
bacyclin failed to reach the maximal relaxation of
rabbit mesenteric artery attained with PGI2, (SE)-
carbacyclin and PGE1. In fact, at 280 ng, (5Z)-car-
bacyclin elicited less than 40% of the maximal res-
ponse.
Again, this result suggested that (5Z)-carbacyclin
might be a partial agonist. This is confirmed by the
data in Figure 9, which show that this carbacyclin
antagonized the effects of PGI2, decreasing the relaxa-
tion elicited by the latter, when they were coadminis-
tered. That the lower response was not due to a
decreased sensitivity of the mesenteric artery is de-
monstrated by the unaltered response to the sub-
sequent administration of PGO2.
Discussion
(SE)- and (5Z)-carbacyclin are two chemically stable
analogues of prostacyclin, the former being isosteric








Figure 9 Relaxation of rabbit mesenteric artery by prostacyclin (PGI2) and (5Z)-carbacyclin ((5Z)-C) alone, and their
combined effect.
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mimic the effect of PGI2 and PGE1, in that they are
inhibitors of platelet aggregation in vitro and ex vivo
and they lower arterial blood pressure (Whittle et al.,
1980). Since inhibition of platelet aggregation and
vasodilatation are supposed to be mediated by in-
creases in intracellular cyclic AMP levels, the study of
adenylate cyclase stimulation by these prostaglandins
might shed some light on the nature of the receptor
involved in these phenomena. We have used PGEI as a
reference compound in these studies, since we have
demonstrated that it displays the same efficacy as
prostacyclin, and, by means of binding (Lombroso et
al., 1984) or additivity studies (Nicosia et al., 1987),
that it acts through identical receptors.
In human platelet membranes, (SE)- and (5Z)-car-
bacyclins activate adenylate cyclase to the same extent
as PGEI, and therefore as PGI2. The effect of (5E)-
carbacyclin is in agreement with the data of Stein &
Martin (1984), and was expected since this prostaglan-
din raises cyclicAMP levels (Ceserani et al., 1980), and
its anti-aggregating effect is potentiated by the phos-
phodiesterase inhibitor, theophylline (Whittle et al.,
1980; Morita et al., 1980).
The stimulation of adenylate cyclase activity
correlates well with the functional response of plate-
lets, in that the rank order of potency for enzyme acti-
vation is paralleled by that found for inhibition of
platelet aggregation (Whittle et al., 1980). Further-
more, PGE1 and the carbacyclins display parallel
dose-response curves and attain the same maximal
effect both in adenylate cyclase activation and in
platelet aggregation studies.
The pattern is completely different in myocytes
cultured from rabbit mesenteric artery. In this system,
while (5E)-carbacyclin activates adenylate cyclase to
the same extent as PGEI, the (5Z) epimer has a
markedly lower efficacy, the maximal stimulation of
the enzyme being only 40-45% of that obtained with
the other prostaglandins. It is noteworthy that both in
smooth muscle and platelets the enzyme stimulation is
in very good aggreement with the biological res-
ponse; in fact, we demonstrate that (5Z)-carbacyclin is
less efficient (40% of maximal) than the other pros-
taglandins in the relaxation ofrabbit mesenteric artery
in vitro.
The fact that (5Z)-carbacyclin is unable to produce
the maximal effect elicited by PGI2 or PGE, could be
explained on the basis of two different hypotheses:
either (5Z)-carbacyclin interacts with an independent
receptor, different from the one shared by prostacyclin
and other analogues, and possesses a lower intrinsic
activity, or this carbacyclin behaves as a partial
agonist at the prostacyclin receptor. That the latter is
the more likely hypothesis is demonstrated by the
experiments illustrated in Figures 5 to 7, which show
that (5Z)-carbacyclin is able to decrease the stimula-
tion of adenylate cyclase elicited by either PGE1 or
PGI2. This carbacyclin seems therefore to be endowed
with antagonistic properties at the PGE1/PGI2 recep-
tor, as one would expect from a partial agonist (Ariens
et al., 1964).
While it is true that such antagonist properties
appear only at relatively high concentrations, the
relevance of our finding is supported by similar results
which have been obtained recently with another PGI2
analogue having the same configuration as (5Z)-car-
bacyclin at carbon 5: in fact, FCE 22176, i.e. (5Z)-13,
14-didehydro-20-methyl-carboprostacyclin, has been
shown to be a competitive antagonist of PGI2 on
guinea-pig trachea and atrium (Fassina et al., 1985).
These results, taken together with our present find-
ings, suggest that position 5 is a key one in determining
the mode of interaction of PGI2 with its receptors.
Whittle et al. (1980, 1984) had investigated the
selectivity of a number of PGI2 analogues, including
(5Z)-carbacyclin, by means of the 'selectivity ratio',
that is by calculating the ratio ofthe relative potency of
the analogue to prostacyclin as a vasodepressor in vivo
and a platelet inhibitor in vitro. The differences in this
index obtained with a series of compounds seemed to
indicate that some intrinsic differences exist between
the platelet and vascular receptor for PGI2. However,
as the authors themselves pointed out (Whittle et al.,
1984), the 'selectivity ratio' must be interpreted with
caution, mainly because it is inferred from the compar-
ison of in vivo and in vitro data, which might be
affected by differences in metabolism or phar-
macodynamics among the various analogues.
Therefore, our results give evidence, obtained direc-
tly at the receptor-binding site level, of the possibility
of discriminating between the platelet and vascular
PGI2 receptors, and suggest that the moiety compris-
ing carbon S might play an important role in the design
of an analogue with a high degree of selectivity
between the cardiovascular and anti-platelet effects.
We thank Dr B.J.R. Whittle, The Wellcome Research
Laboratories, Beckenham, Kent, UK, for the generous gift of
prostaglandins and for a helpful discussion. We are indebted
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References
ARIENS, E.J., SIMONIS, A.M. & VAN ROSSUM, J.M. (1964).
Drug-receptor interaction: interaction of one or more
drugs with one receptor system. In Molecular Phar-
macology, Vol. 1. ed. Ariens, E.J. pp. 171-180, New
York: Academic Press.
BORN, G.V.R. (1962). Aggregation of blood platelets by
5Z-CARBACYCLIN INTERACTION WITH PGI2 RECEPTORS 261
adenosine diphosphate and its reversal. Nature, 194,
927-929.
BRADFORD, M. (1976). A rapid and sensitive method for the
quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal. Biochem., 72,
248-254.
CESERANI, R., GROSSONI, M., LONGIAVE, D., MIZZOTTI,
B., POZZI, O., DEMBINSKA-KIEC, A. & BIANCO S. (1980).
dL-9a-deoxy-9a-methylene-PGI2 (a stable prostacyclin
derivative): preliminary pharmacological data. Prosta-
glandins Med., 5, 13 1-139.
FASSINA, G., FROLDI, G. & CAPARROTTA, L. (1985). A
stable isosterically modified prostacyclin analogue, FCE-
22176, acting as a competitive antagonist to prostacyclin
in guinea-pig trachea and atria. Eur. J. Pharmac., 113,
459-460.
FERREIRA, S.H. & COSTA, F.S. (1976). A laminar flow
technique with much increased sensitivity for the detec-
tion of smooth muscle stimulating substances. Eur. J.
Pharmac., 39, 379- 381.
GORMAN, R.R., BUNTING, S. & MILLER, O.V. (1977).
Modulation of human platelet adenylate cyclase by
prostacyclin (PGX). Prostaglandins, 13, 377-387.
JOHNSON, R.A., MORTON, D.R., KINNER, J.H., GORMAN.
R.R., McGUIRE, J.C., SUN, F.F., WHITTAKER, N., BUNT-
ING, S., SALMON, J., MONCADA, S. & VANE, J.R. (1976).
The chemical structure of prostaglandin x (prostacyclin).
Prostaglandins, 12, 915-928.
KATZ, M.S., KELLY, T.M., PINEYRO, M.A. & GREGERMAN,
R.I. (1978). Activation of epinephrine and glucagon-sen-
sitive adenylate cyclases of rat liver by cytosol protein
factors. Role in loss of enzyme activities during prepara-
tion of particulate fractions, quantitation and partial
characterization. J. Cyclic Nucleotide Res., 5, 389-407.
KUKOVETZ, W.R., HOLZMANN, S., WURM, A. & POCH, G.
(1979). Prostacyclin increasescAMP in coronary arteries.
J. Cyclic Nucleotide Res., 5, 469-476.
LOMBROSO, M., NICOSIA, S., PAOLETTI, R., WHITTLE,
B.J.R., MONCADA, S. & VANE, J.R. (1984). The use of
stable prostaglandins to investigate prostacyclin (PGI2)-
binding sites and PGI2-sensitive adenylate cyclase in
human platelet membranes. Prostaglandins, 27, 321- 333.
MILLER, O.V., AIKEN, J.W., HEMKER, D.P., SHEBUSKI, R.J.
& GORMAN, R.R. (1979). Prostacyclin stimulation of dog
arterial cyclic AMP levels. Prostaglandins, 18, 915-925.
MONCADA, S., GRYGLEWSKI, R., BUNTING, S. & VANE, J.R.
(1976). An enzyme isolated from arteries transforms
prostaglandin endoperoxides to an unstable substance
that inhibits platelet aggregation. Nature, 263, 663-665.
MONCADA, S., FERREIRA, S.H. & VANE, J.R. (1978).
Bioassay of prostaglandins and biologically active sub-
stances derived from arachidonic acid. In Advances in
Prostaglandin and Thromboxane Research. volume 5. ed.
Frolich J.C. pp. 211-236. New York: Raven Press.
MORITA, A., MORI, M., HASEGAWA, K., KOJIMA, K. &
KOBAYASHI, S. (1980). Anti-platelet aggregating and
disaggregating activities of 6, 9-methano PGI2. Life Sci.,
27, 695-701.
MORTON, D.R., BUNDY, G.L. & NISHIZAWA, E.E. (1979).
Five-membered ring-modified prostacyclin analogs. In
Prostacyclin. ed. Vane J.R. & Bergstrom S. pp. 31-41.
New York: Raven Press.
NICOSIA, S., OLIVA, D., NOE', M.A., CORSINI, A., FOLCO.
G.C. & FUMAGALLI, R. (1987). PGI2 receptors in vas-
culature and platelets: 5Z-carbacyclin discriminates bet-
ween them. In Advances in Prostaglandin, Thromboxane
and Leukotriene Research, Vol. 16, ed. Samuelsson P.,
Paoletti, R. & Ramwell P. New York: Raven Press, (in
press).
OLIVA, D., BERNINI, F., CORSINI, A. & NICOSIA, S. (1984a).
6-keto-prostaglandin El-sensitive adenylate cyclase and
binding sites in membranes from platelet and cultured
smooth muscle cells. Biochem. Pharmac., 33, 3755-3758.
OLIVA, D., NOE', A., NICOSIA, S., BERNINI, F., FUMAGALLI,
R., WHITTLE, B.J.R., MONCADA, S. & VANE, J.R. (I1984b).
Prostacyclin-sensitive adenylate cyclase in cultured
myocytes: differences between rabbit aorta and mesen-
teric artery. Eur. J. Pharmac., 105, 207-213.
ROSS, R. (1971). The smooth muscle cell. J. cell. Biol., 50,
172-186.
SALOMON, Y., LONDOS, C. & RODBELL, M. (1974). A highly
sensitive adenylate cyclase assay. Anal. Biochem., 58,
541- 548.
STEIN, J.M. & MARTIN, B.R. (1984). The effect ofcarbacyclin,
a prostaglandin analogue on adenylate cyclase activity in
platelet membranes. FEBS Lett., 165, 290-292.
TATESON, J.E., MONCADA, S. & VANE, J.R. (1977). Effects of
prostacyclin (PGX) on cyclic AMP concentrations in
human platelets. Prostaglandins, 13, 389-396.
TREMOLI, E., MADERNA, P., SIRTORI, M. & SIRTORI, C.R.
(1979). Platelet aggregation and malondialdehyde forma-
tion in type IIA hypercholesterolemic patients. Haemo-
stasis, 8, 47-53.
WHITTLE, B.J.R. & MONCADA, S. (1984). Antithrombotic
assessment and clinical potential of prostacyclin
analogues. In Progress in Medicinal Chemistry, Volume
21. ed. Ellis G.P. & West G.B. pp. 238-279. Amsterdam:
Elsevier Science Publishers B.V.
WHITTLE, B.J.R., MONCADA, S., WHITING, F. & VANE, J.R.
(1980). Carbacyclin-a potent stable prostacyclin
analogue for the inhibition of platelet aggregation. Pros-
taglandins, 19, 605-627.
(Received August 1, 1986
Accepted September 2, 1986.)
